Intelligent Bio's Stock Surges Past 120% Following Breakthrough Manufacturing Alliance with Syrma Johari

Strategic Production Partnership Drives Margin Expansion and Supply Chain Optimization

Intelligent Bio Solutions Inc. (INBS) experienced a dramatic market rally today, with shares climbing 119% following the announcement of a transformative manufacturing collaboration with Syrma Johari MedTech Ltd. The partnership represents a pivotal milestone for the company’s Intelligent Fingerprinting Drug Screening Reader, a portable detection system designed to identify recent substance use in workplace settings.

Cost Efficiency and Production Scaling

The manufacturing agreement with Syrma Johari is projected to deliver substantial financial benefits. The company anticipates annual production cost reductions exceeding 40%, which translates into approximately 20 percentage points of gross margin improvement—a significant enhancement compared to previous manufacturing arrangements. Beyond cost savings, Syrma Johari’s production infrastructure offers approximately four times the current manufacturing capacity of Intelligent Bio, positioning the company to meet scaling demands as commercial expansion accelerates globally.

Product Innovation and Market Reach

The Intelligent Fingerprinting Drug Screening System operates through non-invasive sweat analysis from fingerprints, detecting workplace-prevalent substances including opioids, cocaine, methamphetamine, and cannabis. This technology-driven approach serves dual functions: deterring substance abuse while promoting compliance with corporate health and safety protocols. The system already maintains commercial availability across multiple international markets, spanning Chile, the United Kingdom, Australia, and Scandinavian nations.

Regulatory Pathway and Timeline

In December 2024, Intelligent Bio initiated the FDA 510(k) premarket notification process for U.S. market authorization. While the FDA requested supplementary documentation, the company is actively addressing these inquiries with plans to submit a revised notification. The organization is targeting a 2026 entry into the American market, contingent upon obtaining regulatory clearance. This timeline underscores the company’s commitment to scaling operations across geographies.

Supply Chain Resilience

The Syrma Johari partnership strengthens Intelligent Bio’s global manufacturing footprint while reducing single-supplier dependency. This diversification bolsters supply chain resilience during periods of market volatility or demand fluctuations, a strategic advantage as the company accelerates its commercial rollout.

Market Response and Corporate Action

The market reacted decisively to this announcement, propelling INBS to $8.97, reflecting a 119% daily gain. Notably, the company executed a 1-for-10 reverse stock split effective December 16, 2025, which preceded this positive development. The confluence of manufacturing optimization and international regulatory progress has positioned Intelligent Bio for sustained growth momentum as it approaches U.S. market entry.